TY - JOUR
T1 - JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms
AU - Eickhardt-Dalbøge, Christina Schjellerup
AU - Nielsen, Henrik V
AU - Fuursted, Kurt
AU - Stensvold, Christen Rune
AU - Andersen, Lee O' Brien
AU - Lilje, Berit
AU - Larsen, Morten Kranker
AU - Kjaer, Lasse
AU - Christensen, Sarah Friis
AU - Knudsen, Trine Alma
AU - Skov, Vibe
AU - Sørensen, Anders Lindholm
AU - Ellervik, Christina
AU - Olsen, Lars Rønn
AU - Christensen, Jens Jørgen Elmer
AU - Nielsen, Xiaohui Chen
AU - Hasselbalch, Hans Carl
AU - Ingham, Anna Cäcilia
N1 - © 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2024/5
Y1 - 2024/5
N2 - BACKGROUND: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis.METHODS: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation.RESULTS: MPN patients had a higher observed richness (median, 245 [range, 49-659]) compared with HCs (191.5 [range, 111-300; p = .003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p < .001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation.CONCLUSION: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.
AB - BACKGROUND: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis.METHODS: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation.RESULTS: MPN patients had a higher observed richness (median, 245 [range, 49-659]) compared with HCs (191.5 [range, 111-300; p = .003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p < .001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation.CONCLUSION: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.
U2 - 10.1111/ejh.14169
DO - 10.1111/ejh.14169
M3 - Article
C2 - 38226781
SN - 0902-4441
VL - 112
SP - 776
EP - 787
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 5
ER -